Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
INTENSIVE CONCOMITANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED UNRESECTABLE SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A PHASE-II STUDY OFRADIOTHERAPY WITH CISPLATIN AND 7-WEEK CONTINUOUS INFUSIONAL FLUOROURACIL
Autore:
WIBAULT P; BENSMAINE MEA; DEFORNI M; ARMAND JP; BERNAL ET; GUILLOT T; RECONDO G; DOMENGE C; JANOT F; BOREL C; LUBOINSKI B; ESCHWEGE F; CVITKOVIC E;
Indirizzi:
HOP PAUL BROUSSE,SMST,12-24 AVE PAUL VAILLANT COUTURIER F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,DEPT RADIOTHERAPY F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,DEPT MED F-94805 VILLEJUIF FRANCE INST GUSTAVE ROUSSY,DEPT HEAD & NECK SURG F-94805 VILLEJUIF FRANCE
Titolo Testata:
Journal of clinical oncology
fascicolo: 4, volume: 14, anno: 1996,
pagine: 1192 - 1200
SICI:
0732-183X(1996)14:4<1192:ICCILA>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
RADIATION-THERAPY; INDUCTION CHEMOTHERAPY; PROGNOSTIC FACTORS; CANCER; 5-FLUOROURACIL; LEUCOVORIN; COMBINATION; BLEOMYCIN; RECURRENT; TUMORS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
50
Recensione:
Indirizzi per estratti:
Citazione:
P. Wibault et al., "INTENSIVE CONCOMITANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED UNRESECTABLE SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK - A PHASE-II STUDY OFRADIOTHERAPY WITH CISPLATIN AND 7-WEEK CONTINUOUS INFUSIONAL FLUOROURACIL", Journal of clinical oncology, 14(4), 1996, pp. 1192-1200

Abstract

Purpose: To evaluate an intensive concomitant chemoradiotherapy protocol of conventional radiotherapy with intermittent cisplatin (CDDP) and continuous-infusion fluorouracil (5-FU) in unresectable, locally advanced squamous cell carcinoma of the head and neck (SCCHN). Patients and Methods: Fifty-seven patients with unresectable stage IV MO disease(International Union Against Cancer [UICC]/American Joint Committee on Cancer [AJCC], 1987) received radiotherapy 70 Gy followed by CDDP 80mg/m(2) and 5-FU 300 mg/m(2)/d. Response was assessed 2 months after treatment completion. Results: Thirty patients (52%) received the fulltreatment schedule; 53 (93%) received full-dose radiotherapy, while 48 (84%) were given at least 75% of the planned chemotherapy doses. Severe mucositis [World Health Organization [WHO]) grade 3 to 4 was the limiting toxicity and was seen in 79% of patients. The median time for mucositis resolution was 8 weeks. Other toxicities were generally manageable, but there were four treatment-related deaths (7%). Fifty patients were assessable for activity, with an overall response rate of 70%(95% confidence interval [CI], 58% to 82%). Complete response (CR) and partial response (PR) rates were 42% and 28%, respectively. Conclusion: This simultaneous combined-modality regimen was feasible at the cost of severe mucosal toxicity, which required hospitalization with nutritional, parenteral, and hydroelectrolytic support. The high responserate achieved (70%) did not translate into improved survival, probably due to patient eligibility. The likelihood of cure of this high-tumoral-volume patient population remains low (similar to 10%), despite the association of two therapeutic modalities at full standard therapeutic intensity. (C) 1996 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 17:00:26